HARBIN, China, March 22 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. (“China Sky One Medical” or “the Company”) , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People’s Republic of China (“PRC”), today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.
“We look forward to the near-term launch of several products from our R&D pipeline and are now working on the sales forecast for these products diligently. Looking ahead, we are committed to provide more transparency to the investment community about the progress of our rich R&D pipeline. We expect to continue to diversify our rich product portfolio to strengthen the Company’s competitive position and support sustainable long-term growth,” said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (“TDR”), Harbin First Bio-Engineering Company Limited (“First”), Heilongjiang Tianlong Pharmaceutical, Inc. (“Tianlong”) and Peng Lai Jin Chuang Pharmaceutical Company (“Jin Chuang”) the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include the production timeline and its effect on the Company’s operational results. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the ability to launch new products, market acceptance of new product launches, the effect of changing economic conditions in The People’s Republic of China, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
CONTACT: Stanley Hao, CFO of China Sky One Medical, Inc.,
+86-451-8703-2617, stanleyhao@cski.com.cn; or Ms. Lei Huang, Account
Manager, +1-646-833-3417, lei.huang@ccgir.com, or Ms. Mabel Zhang, Vice
President, +1-310-954-1353, mabel.zhang@ccgir.com, both of CCG Investor
Relations
Web site: http://www.cski.com.cn/
